UNSPSC 51162737: Pseudoephedrine tannate

This classification denotes an alpha-adrenergic agonist with the molecular formula C76H52O46.C10H15NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 82W1IJ29AT. European Medicines Agency schedules pseudoephedrine tannate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20399. Most nations, for tariff and trade purposes, schedule pseudoephedrine tannate under HS 29394200 and SITC 54144. As of Q4 2014, PSEUDOEPHEDRINE TANNATE remains US FDA's Preferred Term for this commodity. SMILES: none.

UNSPSC 51162737 Pseudoephedrine tannate is a Commodity code representing pharmaceutical products and OTC medicines procured by state and local health agencies. The recent opportunities tagged under this code show little direct relevance to pseudoephedrine tannate specifically; instead, they reflect broader pharmaceutical and health-supply procurement by state and local bodies. Seminole County, Florida issued an IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 safe drug deactivation systems annually), while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, including Oregon. State and local pharmaceutical procurement involves county health departments, state purchasing offices, and regional cooperative purchasing alliances as issuing bodies.

Activity under this code spans multiple states, with recent solicitations in Florida and Minnesota (and cooperating jurisdictions in Oregon). The Seminole County naloxone IFB (S1070000015802) was due July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, while the MMCAP RFP (posted January 20, 2026) was due March 26, 2026, with awarded vendors' products to be available by May 1, 2026, and contracts effective July 1, 2026. Both solicitations required vendors to meet federal compliance standards including cGMP certification, E-Verify authorization, and specific insurance thresholds. The MMCAP procurement emphasized price competitiveness (75 percent weight), with vendors required to maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) and charged a 3 percent administrative fee on all contract purchases.